ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ObsEva SA (OBSV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9992
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women’s reproductive health and pregnancy. The company’s product portfolio comprises pipeline products which is being developed to control preterm labor by reducing inflammation, decreasing uterine contractions and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

ObsEva SA (OBSV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises US$34.8 Million In Series A Financing 13
Licensing Agreements 14
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
Equity Offering 17
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA – Key Competitors 23
ObsEva SA – Key Employees 24
ObsEva SA – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2018: ObsEva reports third quarter 2018 financial results and provides business update 26
Aug 08, 2018: ObsEva reports second quarter 2018 financial results and provides business update 28
May 16, 2018: ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update 30
Mar 09, 2018: ObsEva Reports Fourth Quarter And Year-End 2017 Financial Results And Provides Business Update 31
Nov 14, 2017: ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update 33
Aug 15, 2017: ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 18, 2017: ObsEva Reports First Quarter 2017 Financial Results and Business Update 35
Corporate Communications 36
Jul 25, 2018: ObsEva Expands Executive Team Hiring a Chief Commercial Officer 36
Jul 13, 2018: ObsEva to start trading on the SIX Swiss Exchange 37
Jun 01, 2018: ObsEva to Seek SIX Share Listing 38
Feb 01, 2018: Dr. Ernest Loumaye, CEO of ObsEva returns to work following a personal leave for medical reasons 39
Jan 17, 2017: ObsEva Expands Leadership Team and Board of Directors with Industry Veterans 40
Product News 41
06/29/2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting 41
03/17/2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor 42
03/01/2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting 43
Clinical Trials 44
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor 44
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting 45
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 46
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
ObsEva SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises US$34.8 Million In Series A Financing 13
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA, Key Competitors 23
ObsEva SA, Key Employees 24
ObsEva SA, Subsidiaries 25

List of Figures
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ObsEva SA (OBSV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • NNEGC Energoatom:企業の戦略的SWOT分析
    NNEGC Energoatom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Sonivate Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sonivate Medical Inc (Sonivate Medical) is a medical device company that develops and manufactures diagnostic imaging technologies. The company offers dual-plane ultrasound probe, a finger-mounted ultrasound probe that leverages innate human hand eye coordination, which with any ultrasound s …
  • KONE Corporation:企業のM&A・事業提携・投資動向
    KONE Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's KONE Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Mersana Therapeutics Inc (MRSN)-製薬・医療分野:企業M&A・提携分析
    Summary Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp, is a biotechnology company that develops immunoconjugate therapies to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes its Fleximer an …
  • Endeavour Mining Corporation:企業の戦略・SWOT・財務情報
    Endeavour Mining Corporation - Strategy, SWOT and Corporate Finance Report Summary Endeavour Mining Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • American Overseas Group Limited
    American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report Summary American Overseas Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Australian Broadcasting Corporation:企業の戦略的SWOT分析
    Australian Broadcasting Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Dairyland Power Cooperative:企業の発電所・SWOT分析2018
    Dairyland Power Cooperative - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Pt Bakrieland Development Tbk
    Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bakrieland Development Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bangkok Bank Public Co Ltd:戦略・SWOT・企業財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lego AS:企業の戦略的SWOT分析
    Lego AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Betco Corp:企業の戦略的SWOT分析
    Betco Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Shikoku Electric Power Co., Inc.:企業の戦略・SWOT・財務情報
    Shikoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Shikoku Electric Power Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Black Stone Minerals LP (BSM):企業の財務・戦略的SWOT分析
    Summary Black Stone Minerals LP (Black Stone) is a mining and minerals exploration and development company that explores and produces mineral deposits. The company's services include participating on a working interest basis when economics are favorable, leasing minerals to exploration and productio …
  • Bell Helicopter Textron Inc.:企業の戦略・SWOT・財務情報
    Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report Summary Bell Helicopter Textron Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Targa Resources Partners LP (NGLS PR A)-石油・ガス分野:企業M&A・提携分析
    Summary Targa Resources Partners LP (Targa Resources) is an independent midstream company. The company provides midstream natural gas and natural gas liquids (NGL) services. Targa Resources carries out the gathering, compressing, treating, processing and selling of natural gas, and storing, fraction …
  • WCCT Global Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary WCCT Global Inc (WCCT Global) is a contract research organization that offers early drug development and late phase CRO services. The organization provides CRO solutions, clinical development and clinical support services. Its CRO solutions include project management, clinical monitoring, ph …
  • Kimball International Inc (KBAL):企業の財務・戦略的SWOT分析
    Kimball International Inc (KBAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆